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Guidelines and Guidance
Setting Research Priorities To Reduce Global 
Mortality from Childhood Diarrhoea by 2015
Olivier Fontaine*, Margaret Kosek, Shinjini Bhatnagar, Cynthia Boschi-Pinto, Kit Yee Chan, Christopher Duggan, Homero 
Martinez, Hugo Ribeiro, Nigel C. Rollins, Mohammed A. Salam, Mathuram Santosham, John D. Snyder, Alexander C. Tsai, 
Beth Vargas, Igor Rudan
Childhood diarrhoea still claims nearly 2 million lives each year and remains responsible for 18% of all child deaths [1,2]. Regardless of this, research 
interest in this disease has been steadily decreasing after 
the development of cost-effective interventions in the 1980s 
[3]. In addition, the amount of available research funds 
per disability-adjusted life year (DALY) are several orders 
of magnitude lower for diarrhoea when compared to some 
other diseases, such as autism or diabetes type 2 [4]. The 
UN’s Millennium Development Goal #4 (MDG4) states 
that childhood mortality should be reduced by two thirds 
between 1990 and 2015 [5], but recent estimates show that 
the progress in mortality reduction has not accelerated in 
comparison to 30 years ago [2]. Therefore this MDG target 
is likely to be missed. However, the reduction of child deaths 
by two thirds could be achieved by 2015 if presently available 
cost-effective interventions were delivered to those who need 
them most, and if there were sufficient financial resources to 
ensure their delivery [6,7].
Why is greater progress not being achieved? One of the key 
reasons is lack of knowledge on how to implement existing 
cost-effective interventions and on how to achieve greater 
coverage of these interventions in low-resource settings [8,9]. 
This gap in knowledge can only be filled by appropriately 
targeted research. To assist donors in understanding the 
potential of different research avenues to contribute to 
reducing the burden of disease and disability, the Child 
Health and Nutrition Research Initiative (CHNRI) of the 
Global Forum for Health Research recently developed a 
methodology that allows systematic listing and transparent 
scoring of many competing research options, thus exposing 
their strengths and weaknesses [10–12]. The Department of 
Child and Adolescent Health and Development (CAH) of 
the World Health Organization is currently using the CHNRI 
methodology to develop research priority issues on the major 
causes of child deaths. In this paper, we present the results 
of this research priority-setting process applied by CAH for 
childhood diarrhoea.
The CHNRI Methodology for Priority Setting in Health 
Research Investments
The CHNRI methodology for setting priorities in health 
research investments was proposed as a tool that could be 
used by those who develop research policy and/or invest in 
health research [10–12]. It should assist them to understand 
(i) the full spectrum of research investment options, (ii) the 
potential risks and benefits that can result from investments 
in different research options, and (iii) the likelihood of 
achieving reductions of persisting burden of disease and 
disability through investments. The CHNRI methodology has 
three stages: input from investors and policy makers (defining 
the context and criteria for priority setting); input from 
technical experts (listing and scoring research investment 
options); and input from other stakeholders (weighing the 
criteria according to wider societal system of values) [10–12]. 
The aim of this particular implementation of the CHNRI 
method was to inform key global donors, investors in health 
research (especially of public funds), and international 
agencies on research investment policies that are expected to 
The Guidelines and Guidance section contains advice on conducting and reporting 
medical research.
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address MDG4 in the most effective way if the commitment 
to achieving this goal is genuine. In choosing this context, 
we did not mean to downplay the importance of any other 
issues, such as context-specific issues at local or regional 
levels, the large problem of diarrhoea morbidity, or any 
collateral beneficial effects of investments in diarrhoea 
research expected through improvement of malnutrition and 
other cross-cutting issues [13–15]. Several papers that will be 
informative on research priorities in those specific contexts 
have already been published [16] or are in preparation (I. 
Rudan, personal communication).
Based on CHNRI’s simple conceptual framework (Figure 
1), five criteria were agreed upon: (i) answerability (in an 
ethical way); (ii) likelihood of effectiveness; (iii) likelihood of 
deliverability, affordability, and sustainability; (iv) maximum 
potential impact on burden reduction; and (v) predicted 
impact on equity. The detailed CHNRI methodology process 
is shown in Text S1. The process yielded an initial list of 154 
research questions. The exact scores given to all 154 research 
questions from individual experts are presented in Table 
S1. The final list of priorities with intermediate and final 
priority scores for all 154 research questions is presented in 
Table S2. The full list of technical experts who were invited to 
participate, their expertise, and reasons for non-participation 
from those who declined are presented in Table S3.
Results
Table 1 and Table 2 show the top and bottom 10% of the 154 
research questions. Both tables clearly present the likelihood 
for each research question to comply with each of the five 
chosen priority-setting criteria. Research questions from all 
four broad research domains (epidemiological research; 
health systems and policy research; research to improve 
the existing interventions; and research to develop new 
interventions) feature in both the top 10% and the bottom 
10% of research questions. In Table 1, research questions 
with ranks 1, 2, 8, 9, 11, and 12 represent the domain of 
epidemiological research; 3, 4, 5, 6, and 10 represent health 
systems and policy research; 13 and 14 represent research to 
improve the existing interventions; and 7 and 15 represent 
research to develop new interventions. In Table 2, the same 
is true for questions with ranks 141 and 143 (epidemiological 
research); 147 and 148 (health systems and policy research); 
and 146 (research to improve the existing interventions); 
while the remaining questions represent the “research to 
develop new interventions” domain. This suggests that the 
CHNRI method managed to compare and discriminate 
among questions addressing very different domains of health 
research using the same framework, and that there was no 
systematic bias against research questions from any of the 
four domains.
A look at the top 20% research questions reveals a 
predominance of research questions from the domains 
of “health systems and policy research” (13/31) and 
“epidemiological research” (11/31), while a smaller 
number came from the domains of “research to develop 
new interventions” (4/31) or “research to improve the 
existing interventions” (3/31). This is not surprising because 
technical experts were asked to define research priorities 
that could lead to notable improvements in reduction of 
diarrhoea mortality by the year 2015. This short time frame 
benefited epidemiological questions that proposed to assess 
and confirm the value of existing and available cost-effective 
interventions in different contexts (such as oral rehydration 
solutions, zinc supplementation, exclusive breastfeeding, 
and integrated management of childhood illness). It also 
highlighted the value of investments in health systems and 
policy research that proposed to identify key obstacles to 
delivery, affordability, and sustainability of implementation 
of those interventions on a larger scale. The scores also 
recognised the value of research that aimed to improve 
and optimise the use of those interventions (alone or in 
combination) in different contexts, and to develop entirely 
new interventions and approaches that could assist delivery or 
acceptance of the existing cost-effective interventions.
Among the bottom 20% of research options, the majority 
(18/31) proposed development of entirely new interventions. 
Again, this is not surprising given the specified time frame 
(the year 2015). In addition, eight issues from the domain of 
“epidemiological research”, three from the domain of “health 
systems and policy research”, and two from the domain of 
“improvement of existing interventions” were not seen by 
the scorers as priority. In the large majority of cases, the 
main reason for this was minimal, or entirely non-existent, 
optimism towards their possible impact on reduction of 
diarrhoea mortality within the context defined above (i.e., by 
2015). This was coupled with concerns over effectiveness of 
many of the proposed new interventions, such as developing 
and testing vaccines for Helicobacter pylori and Entamoeba
histolytica, heating weaning foods using solar-powered ovens, 
or investing in improvement of fly control interventions. 
Another prevalent concern common among many low-
scoring options was that they would be more likely to increase 
inequity rather than decrease it, at least by 2015. For example, 
new interventions are very likely to be initially available only 
to those who can afford them. 
Good discrimination between the levels of agreement among 
the scorers on the priority of the 154 questions was achieved 
by calculating “average expert agreement” (see Text S1). The 
scores ranged from 0.55 to 0.91, indicating the proportion of 
scorers that gave the same most frequent answer to an average 
Summary Points
?? ????????????? ????????????????????????????????????????????
on childhood diarrhoea to improve the rate of progress in 
reducing global diarrhoea mortality by 2015, as set out in the 
UN’s Millennium Development Goal #4.
?? ???????????????????????? ?????????????????????????????????????
health research investments recently developed by CHNRI.
?? ?????????????????????????????????????????????? ????
dominated by health systems and policy research questions 
and epidemiological questions, mainly targeted at better 
understanding the barriers towards implementation, 
effectiveness, and optimisation of use of available 
interventions.
?? ? ????????????????????????????????????????????????????
rehydration solution and zinc for the treatment of diarrhoea 
were ranked first.
?? ????? ?????????????????????????? ??????????????????
that, within the context of MDG4, a better balance should be 
achieved between investments in specific domains of health 
research at the global level.
PLoS Medicine  |  www.plosmedicine.org 0248 March 2009  |  Volume 6  |  Issue 3  |  e1000041
question they were asked in relation to a specific research 
investment option. Average expert agreement values are also 
presented for the top and bottom 10% of research questions 
in Tables 1 and 2. Generally, the questions over which the 
greatest level of overall agreement was observed among the 
experts were those that also achieved very high overall research 
priority scores. The greatest points of controversy were the 
research questions related to development of non-existing 
vaccines, entirely new interventions, and education/behaviour 
modification research. 
Discussion
The amount of funding available today for health research 
globally is unprecedented—the research investment market 
has been growing steadily over the past decade to more 
than US$126 billion in 2003 [4]. However, large inequities 
exist between amounts invested in different conditions that 
contribute to the global burden of disease. For example, 
while research on diabetes type 2 receives approximately 
US$102 per DALY, research on diarrhoea receives less than 
US$10 per DALY [4].
Perhaps a more pressing issue is the way in which investors 
manage their risk of investing in different health research 
domains. The risk is highly dependent on the context and 
degree of urgency to identify interventions for particular 
diseases. While high-risk high-profit investment strategies 
(e.g., long-term strategic investments in basic research) may 
be justified in cases of chronic diseases, which can already be 
controlled by changes in diet and lifestyle and do not cause 
imminent threat to life, the situation with childhood diseases 
such as diarrhoea and pneumonia is quite different. Those two 
diseases combined cause more child deaths each year worldwide 
than annual deaths attributable to smoking in all ages, or twice 
as many annual deaths as HIV/AIDS globally [4]. The persisting 
high mortality from diarrhoea in the presence of existing cost-
effective interventions and available resources to implement 
them represents a continuing scandal. Given the consequences 
of the disease in terms of persisting child mortality, the level of 
urgency in dealing with this problem is very different than for 
other chronic diseases that contribute heavily to DALYs. We 
believe that this should be reflected in health research policies 
and investment strategies of the major donors.
doi:10.1371/journal.pmed.1000041.g001
Figure 1: CHNRI’s Conceptual Framework 
This framework shows key steps required to get from investments in health research options to decrease in burden of death, disease, or disability. The 
framework identifies criteria that are important for discriminating among competing research options and judging the likelihood that they will achieve 
their goals: (i) answerability; (ii) effectiveness; (iii) deliverability; (iv) maximum potential for disease burden reduction; and (v) predicted impact on equity 
in the population (right side). These criteria are not necessarily what drive investment decisions in health research today (left side).
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Investment in global health research today would 
benefit from consensus regarding the context, appropriate 
investment strategies, and co-ordination to achieve significant 
reduction of the disease burden in the foreseeable future. 
The present exercise was designed to assist investors and 
policy makers in making more informed choices on their 
investments in health research on diarrhoea by making 
apparent the risks and potential benefits associated with 
investments in a broad spectrum of health research options. 
The expected “profit” from investments is associated 
with generating new knowledge that can be translated 
into development of new (or improvement of existing) 
interventions, which are effective, deliverable, affordable, and 
can reduce the existing burden of disease and disability in an 
equitable way. The risk is associated with research that is not 
likely to be answerable, or that develops products unlikely to 
be effective, deliverable, affordable, or sustainable by those 
who need them most. Investors’ preference for high-risk 
investment in health research is particularly questionable 
when it is occurring in a context that requires urgent 
progress, such as childhood diarrhoea. The focus on complex 
challenges of implementation (i.e., improving health systems, 
training health workers including poorly educated village 
health workers, improving drug supply and delivery at 
community level, etc.), which the exercise highlighted, was 
reflected in many research questions being ranked near the 
top of the list of overall priorities.
The implementation of the CHNRI methodology showed 
that, within the context of MDG4, a better balance should be 
achieved between specific domains of health research. Along 
with continuing strategic long-term investments in vaccines 
and other new interventions, which represent high-risk high-
Table 1: The 15 Research Questions That Achieved the Highest Overall Research Priority Score with Average Expert Agreement 
Related To Each Question
Rank Proposed Research Question Question
Number
Answerable? Effective? Deliverable? Burden
Reduction?
Equitable? RPS AEA
1 What is the acceptability and effectiveness 
of the new reduced osmolarity ORS in clinic 
as well as in the community?
28 100 83 100 80 93 89.7 0.89
2 What is the effectiveness of zinc 
supplementation on the outcome and 
incidence of diarrhoea in the community?
27 100 97 93 70 100 88.7 0.91
3 What are the barriers against appropriate 
use of ORT? 
29a 87 89 100 77 93 87.1 0.91
4 Design locally adapted training programmes 
to orient health workers on IMCI
70 87 90 100 70 100 86.2 0.87
5 What is the impact of IMCI in different 
population groups on timely identification 
and treatment of acute diarrhoeas?
68 100 68 96 73 93 84.3 0.83
6 Identify cost-effective, sustainable methods 
for community-based promotion and 
support for early initiation and continuation 
of breastfeeding during first 6 months of life 
and prolonged breastfeeding
45a 87 89 87 77 90 84.3 0.78
7 Test indicators to determine effectiveness of 
IMCI in treatment of diarrhoea and in terms 
of reducing disease burden
67 97 83 96 73 80 84.0 0.84
8 Assess cost-effectiveness of outpatient 
treatment of diarrhoea with zinc and ORS
59 93 91 100 67 80 83.1 0.86
9 Assess proportion of cases with diarrhoea 
who get appropriate outpatient treatment
61 87 85 77 73 100 82.7 0.79
10 What is the impact of IMCI in different 
population groups on administration and 
promotion of zinc therapy for acute and 
persistent diarrhoeas?
69 97 92 96 53 100 82.3 0.91
11 Assess integration of zinc treatment for 
diarrhoea and zinc in prevention
84 83 83 100 73 80 82.3 0.81
12 Identify means to make community 
promotion of breastfeeding sustainable
91 97 81 77 70 93 81.5 0.80
13 Assess effectiveness of delivery strategies 
to provide zinc and ORT 
82 97 75 80 67 100 81.2 0.83
14 Assess optimal dose and duration of zinc 
for diarrhoea treatment
83 100 83 93 53 90 79.3 0.82
15 What is the acceptability/adherence to zinc 
supplementation for the management of 
diarrhoea in various settings (urban, rural)?
80 100 75 73 60 100 78.5 0.83
aResearch questions 40 and 90, very similar to research question 45, were used as an internal consistency control for the scores obtained from technical experts and were ranked 7th and 
15th on the list of 154 questions; they were not shown in this table. Research question 54, very similar to research question 29, was also used as an internal consistency control and was 
ranked 16th; thus it is also not shown in this table.
Abbreviations: AEA, average expert agreement; IMCI, Integrated Management of Childhood Illness; ORS, oral rehydration salts; ORT, oral rehydration therapy; RPS, research priority score. 
doi:10.1371/journal.pmed.1000041.t001
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profit strategies, the CHNRI process suggested that more 
attention should be given to health policy research, health 
systems research, operations research, and research that 
addresses political, economic, social, cultural, behavioural, 
and infrastructure issues surrounding the problem of child 
mortality. These domains of health research are rarely 
recognised as attractive by investors in health research 
because their results are unlikely to grab the headlines or 
be published in journals with high impact factors or lead to 
patents and commercial products. Yet, they can generate 
new knowledge that can be very helpful in achieving real 
progress in disease burden reduction. The identified 
priorities are also in good agreement with the research 
supported by CAH at present. They emphasise the evaluation 
of existing interventions and the development and testing 
of new delivery approaches of existing interventions. They 
also highlight the value of research on preventive measures 
(breastfeeding, rotavirus vaccination, measles vaccination, 
etc.), with research on new interventions being downplayed 
within the real context.
Advantages and Limitations of the CHNRI 
Methodology
Although the advantages of the CHNRI methodology 
represent a serious attempt to deal with many issues inherent 
to a highly complex process of research investment priority 
setting, there are still concerns over the validity of the CHNRI 
approach and related biases. One of them is related to the 
fact that many possible good ideas (“research investment 
options”) may not have been included in the initial list 
of research options that was scored by the experts, and to 
the potential bias towards items that get the greatest press. 
Another concern over the CHNRI process is that its end 
product represents a possibly biased opinion of a very limited 
group of involved people. In theory, a chosen group of 
experts can have biased views in comparison to any other 
potential groups of experts. Those limitations are described 
and discussed in greater detail in Text S1.
Conclusions
The main message of the process is that the research 
priorities to reduce global mortality from childhood 
diarrhoea within the present context are dominated by health 
systems, policy research, and epidemiological questions. 
These questions are mainly targeted at better understanding 
the barriers towards implementation, effectiveness, 
and optimisation of use of available interventions and 
programmes such as oral rehydration solution, zinc 
supplementation, exclusive breastfeeding, and integrated 
management of childhood illness. If progress towards 
reduction of global diarrhoea mortality is to be improved by 
2015, these are the research questions that are most likely to 
Table 2: The 15 Research Questions That Achieved the Lowest Overall Research Priority Score with Average Expert Agreement 
Related To Each Question
Rank Proposed Research Question Question
Number
Answerable? Effective? Deliverable? Burden
Reduction?
Equitable? RPS AEA
140 Study the effect of zinc on the gut secretory 
mechanisms
129 80 41 50 7 67 42.7 0.66
141 Efficacy/cost-effectiveness studies and education/
behaviour modification research to increase 
consumption of Lactobacillus GG probiotic (impact on 
morbidity and mortality)
50 83 47 46 7 53 41.3 0.65
142 Develop and test EPEC vaccines 124 57 73 42 0 60 38.9 0.71
143 What is the prevalence of coronavirus genotypes? 4 80 43 58 0 39 37.6 0.66
144 Study capacity of Shigella to re-programme invaded 
epithelial cells to produce pro-inflammatory mediators
110 77 50 38 0 57 37.5 0.64
145 Develop molecular techniques for identifying 
(elucidating) new pathogens causing diarrhoea
109 70 53 46 0 50 37.0 0.64
146 Research to improve deliverability and measure 
effectiveness and sustainability of fly control 
interventions (impact on morbidity and mortality)
106 63 29 54 0 67 36.2 0.69
147 Education/behaviour modification research to increase 
utilisation of refrigerators for storage of weaning foods
49 70 57 42 0 40 35.3 0.65
148 Systems and education/behaviour modification 
research to improve water consumed per person per 
day
74 67 32 40 3 57 34.4 0.60
149 Study the capacity of Cryptosporidium to invade 
epithelial cells and its impact on the mucosal immune 
response
116 77 32 46 0 47 34.4 0.64
150 Find practical ways to foster secretion of antibacterial 
peptides as a new therapy 
114 57 45 33 3 53 33.1 0.65
151 Develop new anti-secretory drugs (i.e., enkephalinase 
inhibitors and anti-CFTR)
117 60 55 38 0 43 33.0 0.62
152 Develop and test Campylobacter vaccines 123 57 36 29 0 53 29.9 0.62
153 Develop and test H. pylori vaccines 125 70 9 47 0 47 29.6 0.67
154 Develop and test E. histolytica vaccines 126 57 13 46 0 57 29.4 0.68
Abbreviations: AEA, average expert agreement; CFTR, cystic fibrosis trans-membrane conductance regulator; EPEC, entero-pathogenic E. Coli; RPS, research priority score.
doi:10.1371/journal.pmed.1000041.t002
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be of greatest importance. However, very few donors agencies 
recognise the importance of these domains of health research 
and are willing to readily invest in those options [4,17]. The 
core group of CHNRI experts made several serious attempts 
to influence the key donors and point to this gap and serious 
imbalance in health research investing between “upstream” 
and “downstream” health research. This exercise is the best 
example to date conducted at the global level. 
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